Ayala Pharmaceuticals Entered into a Definitive Merger Agreement with Biosight to Advance Oncology Assets Portfolio
Shots:
- Under the merger agreement, the combined company will operate under Ayala Pharmaceuticals, Inc., and trade on the OTCQX under Ayala’s ticker symbol (“ADXS”). The transaction is expected to close by the end of Q3’23
- The combined company focuses on accelerating a portfolio of oncology assets with the addition of Ayala’s AL102 currently in the registrational (RINGSIDE) study for desmoid tumors and Biosight’s Aspacytarabine (BST-236). After merger completion, the combined company's ownership will be divided with 55% going to Biosight stockholders and 45% to Ayala stockholders
- The results from the P-II portion of the (RINGSIDE) study showed activity of AL102 against progressing desmoid tumors, 50% PR, and 100% DCR in evaluable desmoid tumor patients treated with AL102 (1.2mg, qd). The updated data are expected in 2023
Ref: Ayala Pharmaceuticals | Image: Ayala Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
